Review
[Prostaglandin E1 in therapy of peripheral arterial occlusive disease]
[Article in
German]
Affiliations
- PMID: 1750223
Item in Clipboard
Review
[Prostaglandin E1 in therapy of peripheral arterial occlusive disease]
[Article in
German]
Wien Klin Wochenschr.
1991.
Abstract
The intraarterial and intravenous infusion of prostaglandin E1 (PGE1) today is well established in the therapy of peripheral arterial occlusive disease. This review summarizes the results of pharmacological-clinical studies and the influence of PGE1 on the pathomechanism of ischaemia due to its antithrombotic, leukocyte and endothelial stabilizing properties. Clinical data available on continuous and intermittent infusion for both modes of administration are critically appraised, taking into account more recent data on active metabolites.
Similar articles
-
[Pharmacologic concepts for clinical use of prostaglandin E1].Vasa Suppl. 1991;33:335-6. Vasa Suppl. 1991. PMID: 1788746 Review. German.
-
[Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].Wien Klin Wochenschr. 1991;103(18):554-7. Wien Klin Wochenschr. 1991. PMID: 1750222 German.
-
[Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].Vasa. 2003 Nov;32(4):187-92. doi: 10.1024/0301-1526.32.4.187. Vasa. 2003. PMID: 14694766 Review. German.
-
[Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].Vasa Suppl. 1991;33:346-7. Vasa Suppl. 1991. PMID: 1788752 German.
-
[Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].Wien Klin Wochenschr. 1988 Jul 15;100(14):477-81. Wien Klin Wochenschr. 1988. PMID: 3062905 Clinical Trial. German.